Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2281 to 2290 of 2579 total matches.
Bisphosphonates - Duration of Use Revisited
The Medical Letter on Drugs and Therapeutics • Jun 25, 2012 (Issue 1393)
, atypical fractures of the
femur, and possibly esophageal cancer.1,2 So for how
long should patients take ...
Long-term use of bisphosphonates for prevention and
treatment of osteoporosis has been associated with
osteonecrosis of the jaw, atypical fractures of the
femur, and possibly esophageal cancer. So for how
long should patients take them?
Bellafill for Acne Scars
The Medical Letter on Drugs and Therapeutics • Jun 22, 2015 (Issue 1471)
12 months.1
ADVERSE EFFECTS — Swelling, redness, pain, bruising,
lumps/bumps, itching ...
Bellafill (Suneva), a dermal filler approved earlier for
correction of nasolabial folds, has now also been
approved by the FDA for correction of moderate to
severe, atrophic, distensible facial acne scars on the
cheek in adults ≥21 years old. It is the only dermal filler
approved in the US for correction of facial acne scars.
COVID-19 Update: Pfizer Bivalent Vaccine Booster Dose for Children 6 Months to 4 Years Old
The Medical Letter on Drugs and Therapeutics • Apr 17, 2023 (Issue 1674)
) for children
6 months to 5 years old were authorized earlier.1,2
CLINICAL STUDIES — Expansion of the EUA ...
The FDA has expanded its Emergency Use
Authorization (EUA) for the COVID-19 vaccine
manufactured by Pfizer/BioNTech (Comirnaty) to
permit use of the bivalent formulation (containing
mRNA from the original and BA.4/5 Omicron strains of
SARS-CoV-2) as a booster dose in children 6 months
to 4 years old who completed the primary series with
3 doses of the monovalent formulation ≥2 months
previously. The Pfizer bivalent vaccine had previously
been authorized for use as a booster dose in persons
≥5 years old and as a third primary dose in children 6
months to 4 years old. Booster...
Med Lett Drugs Ther. 2023 Apr 17;65(1674):63-4 doi:10.58347/tml.2023.1674c | Show Introduction Hide Introduction
Low Osmolality Contrast Agents
The Medical Letter on Drugs and Therapeutics • Sep 22, 1989 (Issue 801)
).
SAFETY — In general, serious adverse effects occur in less than 1% of patients injected with
contrast ...
The US Food and Drug Administration recently approved the marketing of ioversol (Optiray - Mallinckrodt), a new iodinated, low-osmolality, non-ionic X-ray contrast agent. Low-osmolality contrast agents are much more expensive, but they provide as good diagnostic quality as older, high-osmolality contrast media and are claimed to be both better tolerated and safer (Medical Letter, 29:43, 1987).
Paclitaxel (Taxol) for Ovarian Cancer
The Medical Letter on Drugs and Therapeutics • May 14, 1993 (Issue 896)
of pre-treating with a corticosteroid and both a histamine H
1
- and a histamine H
2
-antagonist ...
Paclitaxel (Taxol - Bristol-Myers Squibb) is now available in the USA for treatment of metastatic ovarian cancer refractory to other drugs. The new drug is a natural product extracted in small amounts from the inner bark of the Western yew tree found mainly in the Pacific northwest (Taxus brevifolia). Efforts to synthesize the drug have been unsuccessful to date, but a semi-synthetic product (taxotere) prepared from the needles of European yews has shown some promise (R Pazdur et al, J Natl Cancer Inst, 89:1781, 1992), and a fungus (Taxomyces andreanae) growing on the Pacific yew was...
Rimantadine for Prevention and Treatment of Influenza
The Medical Letter on Drugs and Therapeutics • Nov 26, 1993 (Issue 910)
with immunodeficiency (Morbid
Mortal Weekly Rep, 41, RR-9:1, 1992). Giving the drug to both patients and staff can help ...
Rimantadine hydrochloride (Flumadine - Forest), the alpha-methyl derivative of amantadine (Symmetrel, and others), was recently approved by the US Food and Drug Administration for prevention and treatment of influenza A virus infections in adults and for prevention of influenza in children.
Toremifene and Letrozole for Advanced Breast Cancer
The Medical Letter on Drugs and Therapeutics • Apr 10, 1998 (Issue 1024)
97.26
Anastrozole − Arimidex (Zeneca) 1 mg PO qd 187.20
Letrozole − Femara (Novartis) 2.5 mg PO qd ...
The antiestrogen toremifene (Fareston - Schering) and the selective aromatase inhibitor letrozole (Femara - Novartis) have been approved by the FDA for treatment of advanced breast cancer in postmenopausal women.
Cilostazol for Intermittent Claudication
The Medical Letter on Drugs and Therapeutics • May 07, 1999 (Issue 1052)
pentoxifylline or placebo (DL Dawson et al, Circulation, 98 suppl 1:I-12, abstract 58, 1998).
ADVERSE EFFECTS ...
Cilostazol, a phosphodiesterase III inhibitor that has been used in Japan since 1988, has been approved by the FDA for treatment on intermittent claudication due to occlusive peripheral arterial disease.
Pneumococcal Vaccine (Prevnar) For Otitis Media
The Medical Letter on Drugs and Therapeutics • Mar 31, 2003 (Issue 1153)
of injections, the average number of visits
for otitis per year was 1.85 for those given the pneumococcal ...
The heptavalent pneumococcal conjugate vaccine (Prevnar - Wyeth) previously approved by the FDA for prevention of invasive pneumococcal disease in infants and children (Medical Letter 2000; 42:25) has now also been approved for prevention of otitis media. Infants and young children have higher antibody responses to the heptavalent conjugate vaccine (PCV7) than to the older 23-valent pneumococcal polysaccharide vaccine (PPV23) used in adults and older children (D Murray and C Jackson, Mil Med 2002; 167:671).
Eplerenone (Inspra)
The Medical Letter on Drugs and Therapeutics • May 12, 2003 (Issue 1156)
).
PHARMACOKINETICS — Serum concentrations of eplerenone peak 1-2 hours after oral
dosing with or without food ...
Eplerenone (e pler' en one; Inspra - Pharmacia), an aldosterone receptor antagonist similar to spironolactone (Aldactone, and others), has been approved by the FDA, but not yet marketed, for treatment of hypertension. It has also been tried for treatment of heart failure.